1. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. (4th October 2019) Authors: Moro-Sibilot, D; Cozic, N; Pérol, M; Mazières, J; Otto, J; Souquet, P J; Bahleda, R; Wislez, M; Zalcman, G; Guibert, S D; Barlési, F; Mennecier, B; Monnet, I; Sabatier, R; Bota, S; Dubos, C; Verriele, V; Haddad, V; Ferretti, G; Cortot, A Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1985 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗